Key result
The UGT2B7 -161 T allele independently predicted a lower occurrence of cardiotoxicity (OR 0.259) in breast cancer patients undergoing epirubicin/cyclophosphamide-docetaxel adjuvant chemotherapy.
Why the study?
The study aimed to investigate correlations between the UGT2B7 -161 C>T single nucleotide polymorphism and cardiotoxicity in Chinese breast cancer patients undergoing epirubicin/cyclophosphamide-docetaxel adjuvant chemotherapy.
Does the UGT2B7 -161 T allele predict a lower occurrence of cardiotoxicity in breast cancer patients undergoing epirubicin/cyclophosphamide-docetaxel adjuvant chemotherapy?
Cohort (n=427)
No
Does the UGT2B7 -161 T allele predict a lower occurrence of cardiotoxicity in breast cancer patients undergoing epirubicin/cyclophosphamide-docetaxel adjuvant chemotherapy?
The UGT2B7 -161 T allele may serve as a potential biomarker for predicting a lower risk of anthracycline-induced cardiotoxicity in breast cancer patients.
Purpose: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Materials and Methods: 427 BC patients who had underwent surgery were consecutively enrolled in this prospective cohort study. All patients were scheduled to receive EC-D adjuvant chemotherapy regimen, and they were divided into UGT2B7 -161 CC (n=141), UGT2B7 -161 CT (n=196), and UGT2B7 -161 TT (n=90) groups according to their genotypes. Polymerase chain reaction was performed for determination of UGT2B7 -161 genotypes. Cardiotoxicity was defined as an absolute decline in left ventricular ejection fraction (LVEF) of at least 10% points from baseline to a value less than 53%, heart failure, acute coronary artery syndrome, or fatal arrhythmia. Results: LVEF values were lower at cycle (C) 4, C8, 3 months after chemotherapy (M3), M6, M9, and M12 compared to C0 (all p<0.001), in BC patients undergoing EC-D adjuvant chemotherapy. Cardiotoxicity was recorded for 4.2% of the overall population and was lowest in the UGT2B7 -161 TT group (1.1%), compared to UGT2B7 -161 CT (3.1%) and UGT2B7 -161 CC (7.8%) group (p=0.026). Multivariate logistic regression revealed that UGT2B7 -161 T allele could independently predict a low occurrence of cardiotoxicity in BC patients undergoing EC-D adjuvant chemotherapy (p=0.004). Conclusion: A UGT2B7 -161 T allele serves as a potential biomarker for predicting a low occurrence of cardiotoxicity in BC patients undergoing EC-D adjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) conducted a cohort in Breast cancer (n=427). UGT2B7 -161 T allele vs. UGT2B7 -161 CC genotype was evaluated on Occurrence of cardiotoxicity (absolute decline in LVEF of at least 10% points to <53%, heart failure, acute coronary syndrome, or fatal arrhythmia) (OR 0.259, 95% CI 0.103-0.651, p=0.004). The UGT2B7 -161 T allele independently predicted a lower occurrence of cardiotoxicity (OR 0.259) in breast cancer patients undergoing epirubicin/cyclophosphamide-docetaxel adjuvant chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: